RE: Washington Post24 Aug 2020 02:09
grimshady : "NCYT are having to redesign there test because it is ****......... they have months of RND then months of trials and approvals ahead of them."
Ha ha oh wow ! I'm used to reading this sort of hard coping mechanism from distressed investors, but this is such a gross and gullible assertion (aka blatant bullcr4p) that I'm in awe.
I'll address your crass comments so as to inform, not so much you, but other GDR shareholders who might be decent individuals.
1) "Redesign" ? Well we're just making another version (actually two) of the current test in order to reach new markets.
This is Marketing 101. Make a product that the customer wants and release it in a timely manner.
Are you not familiar with this elementary approach ? Well maybe that's why your company has yet to ship a single product, whilst NCYT already sold millions in 130+ countries. Just saying.
2) NCYT's test is "****" ? I wasn't aware of that. Why ? How ? Care to substantiate your claim ?
Because that oh-so-crappy single-gene test has been certified by a bunch of major health authorities, including the WHO, and is being used as a benchmark in scientific studies.
Again, can you say the same about your test ? Thought as much.
3) "Months of R&D and trials" ? Sorry but NCYT isn't GDR.
The release of the two-gene version of our test is scheduled for September. Of this very year.
And that's beside the release of the respiratory testing panel, which will be able to discriminate between Covid-19 and other common viruses. Parallel work makes wonders.
Even assuming this schedule will slip, I very much doubt it'll be as lengthy as you imply.
See, the company you've invested in seems to have a genuinely good product and your portable machine is pretty cool... but (1) that's useless if the management remains somehow unable to sell it, and (2) it doesn't give you the legitimity to baselessly ****talk behind the back of other companies which up to now have a better track record than yours.
Sign In
Follow the stocks
